Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) reported an inducement equity grant under Nasdaq Listing Rule 5635(c)(4) for a newly hired non-executive officer, with a grant date of September 30, 2025.

The company granted 62,232 non-qualified stock options and 34,564 restricted stock units. The options have a ten-year term and an exercise price of $30.08, equal to the closing price on September 30, 2025. RSUs vest 25% annually over four years; options vest 25% after one year then monthly over the remaining three years (1/48th monthly), subject to continued employment.

News Market Reaction

-3.27%

1 alert

-3.27% News Effect

On the day this news was published, RARE declined 3.27%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 62,232 shares of common stock of the company and 34,564 restricted stock units of the company’s common stock to one newly hired non-executive officer employee of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 30, 2025, as an inducement material to the new employee entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates. The stock options vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date and the remainder vesting with respect to 1/48th of the shares underlying the options on each monthly anniversary thereafter, subject to the employee being continuously employed by the company as of such vesting dates. The stock options have a ten-year term and an exercise price of $30.08 per share, equal to the per share closing price of Ultragenyx’s common stock on September 30, 2025.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What did Ultragenyx (RARE) announce on October 3, 2025 about inducement grants?

Ultragenyx reported an inducement grant of 62,232 stock options and 34,564 RSUs to a new non-executive officer, granted September 30, 2025.

What is the exercise price and term for the RARE options granted on September 30, 2025?

The options have a ten-year term and an exercise price of $30.08, equal to the September 30, 2025 closing price.

How do the restricted stock units for the RARE inducement vest?

The 34,564 RSUs vest over four years with 25% vesting on each anniversary, subject to continued employment.

What is the vesting schedule for Ultragenyx's 62,232 stock options (RARE)?

Options vest 25% after one year, then 1/48th of the total shares monthly over the next 36 months, subject to continued employment.

Under which plan and Nasdaq rule were the RARE inducement awards granted?

Awards were granted under the Ultragenyx Employment Inducement Plan as an inducement per Nasdaq Listing Rule 5635(c)(4).